Female patients ≥ 18 years old with histologically confirmed Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube cancer who were enrolled in CAN-003

Able and willing to undergo mononuclear cell (MNC) collection (if required for patients who do not have available Cvac doses)

Were enrolled in CAN-003 and met protocol criteria for progressive disease

Wish to remain in the study and, in the investigator's judgment, the potential benefit of Cvac treatment outweighs the risk

Must be non-pregnant and, if of childbearing potential, must use adequate birth control (hormonal or barrier method of birth control or abstinence) for the duration of the study and for 3 months after study completion

Able to provide written informed consent

White blood cell count (WBC) ≥ 3.0 K/μL, absolute neutrophil count ≥ 1.5 K/μL, hemoglobin ≥ 9.0 g/dL, and platelets ≥100,000/mm\^3

Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study

What this study is about